Cancer and COVID-19: Unmasking their ties.
Cancer
Covid-19
Immunotherapy
Mortality
NSCLC
Journal
Cancer treatment reviews
ISSN: 1532-1967
Titre abrégé: Cancer Treat Rev
Pays: Netherlands
ID NLM: 7502030
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
11
05
2020
revised:
19
05
2020
accepted:
25
05
2020
pubmed:
10
6
2020
medline:
30
7
2020
entrez:
10
6
2020
Statut:
ppublish
Résumé
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) and its clinical manifestation, the coronavirus disease 2019 (COVID19) have rapidly spread across the globe, leading to the declaration of a pandemic. While most present mild symptoms, it appears as though nearly 20% of confirmed patients develop significant complications. These include acute respiratory distress syndrome, septic shock and multi-organ failure, with a 3-6% mortality. A plethora of treatments has been or is being assessed, but to date, none has been proven effective. Management is mainly symptomatic, with organ support for the critically ill. Several reports, mainly case series, from across the world have concluded that patients with malignancy appear more susceptible to severe infection and mortality from COVID-19. This could be attributed to immunosuppression, co-existing medical conditions and underlying pulmonary compromise which is often the case in lung malignancy. Patients with haematological cancer and those who are receiving active chemotherapy treatment may be at greatest risk due to increased immunosuppression. This pandemic tested the resilience of worldwide health-care systems in an unprecedented manner. It has forced oncologists to rethink the entire diagnostic and therapeutic process, based on the local prevalence and impact of COVID-19. In this review we will discuss the impact of COVID-19 on patients affected by cancer, their diagnosis and management, as well as the pathophysiology of COVID-19 induced acute respiratory distress symptoms and currently investigated treatment approaches.
Identifiants
pubmed: 32516704
pii: S0305-7372(20)30079-7
doi: 10.1016/j.ctrv.2020.102041
pmc: PMC7831797
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102041Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Apr 12;43(4):297-301
pubmed: 32125132
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Open Forum Infect Dis. 2020 Mar 21;7(3):ofaa102
pubmed: 32258207
Cancer Discov. 2020 Jul;10(7):935-941
pubmed: 32357994
Cell Mol Immunol. 2020 Jun;17(6):647-649
pubmed: 32313207
Nature. 2005 Jul 7;436(7047):112-6
pubmed: 16001071
Microbiol Mol Biol Rev. 2012 Mar;76(1):16-32
pubmed: 22390970
JAMA Oncol. 2019 Jul 1;5(7):934-935
pubmed: 31145420
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Sci Signal. 2010 Jan 19;3(105):cm1
pubmed: 20086235
Am J Physiol. 1994 Nov;267(5 Pt 1):L564-8
pubmed: 7526705
Transplant Proc. 1973 Mar;5(1):943-7
pubmed: 4735211
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Crit Care. 2020 May 19;24(1):241
pubmed: 32430057
Circ Res. 2006 Mar 3;98(4):463-71
pubmed: 16514079
Clin Infect Dis. 2020 Jul 28;71(15):732-739
pubmed: 32150618
Nat Rev Immunol. 2013 Mar;13(3):176-89
pubmed: 23411799
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Biosci Trends. 2020 Mar 16;14(1):72-73
pubmed: 32074550
Lancet Infect Dis. 2020 Jul;20(7):773
pubmed: 32171390
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
JCI Insight. 2019 Feb 21;4(4):
pubmed: 30830861
J Infect Dis. 2015 Jan 1;211(1):80-90
pubmed: 25030060
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
Signal Transduct Target Ther. 2020 Apr 28;5(1):57
pubmed: 32341331
J Exp Med. 2005 Aug 1;202(3):415-24
pubmed: 16043521
Clin Infect Dis. 2020 Jul 28;71(15):778-785
pubmed: 32198501
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
Front Immunol. 2013 Jul 15;4:182
pubmed: 23874332
Nature. 2002 Jun 20;417(6891):822-8
pubmed: 12075344
Intensive Care Med. 2020 Apr;46(4):586-590
pubmed: 32125455
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
J Pathol. 2004 Jun;203(2):622-30
pubmed: 15141376
Crit Care. 2017 Sep 7;21(1):234
pubmed: 28877748
Int J Mol Sci. 2019 Sep 25;20(19):
pubmed: 31557974
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Int J Antimicrob Agents. 2007 Oct;30(4):297-308
pubmed: 17629679
Saudi J Biol Sci. 2020 Oct;27(10):2531-2538
pubmed: 32336927
Blood. 2019 Dec 12;134(24):2149-2158
pubmed: 31697826
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
J Clin Invest. 2020 Apr 1;130(4):1545-1548
pubmed: 32167489
N Engl J Med. 2020 Jun 11;382(24):2285-2287
pubmed: 32267650
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Lancet Oncol. 2020 May;21(5):629-630
pubmed: 32247319
Lancet Oncol. 2019 Jan;20(1):e54-e64
pubmed: 30614479
Immunotherapy. 2020 Apr;12(5):269-273
pubmed: 32212881
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Signal Transduct Target Ther. 2020 Feb 21;5(1):18
pubmed: 32296012
Crit Care Med. 2016 Feb;44(2):275-81
pubmed: 26584195
JAMA. 2020 Apr 28;323(16):1545-1546
pubmed: 32167538
Nat Med. 2005 Aug;11(8):875-9
pubmed: 16007097
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Clin Lung Cancer. 2003 Jul;5(1):46-62
pubmed: 14596704
Annu Rev Med. 1989;40:431-46
pubmed: 2658759
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Ann N Y Acad Sci. 2000 Jun;908:244-54
pubmed: 10911963
Acta Biomed. 2020 Apr 10;91(3-S):175-179
pubmed: 32275287
Cell. 2020 May 14;181(4):905-913.e7
pubmed: 32333836
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Clin Transl Immunology. 2020 Oct 14;9(10):e1192
pubmed: 33082954
Annu Rev Immunol. 1993;11:571-611
pubmed: 8476573
Mod Pathol. 2020 Jun;33(6):1007-1014
pubmed: 32291399
ESMO Open. 2020 Apr;5(2):e000765
pubmed: 32245904
Comp Med. 2007 Oct;57(5):450-9
pubmed: 17974127
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
Clin Pharmacokinet. 2013 Sep;52(9):783-92
pubmed: 23681967